New pulsed field ablation device aims to relieve prostate troubles

NCT ID NCT06965582

ENROLLING_BY_INVITATION Symptom relief Sponsor: ALPFA Medical Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing a new device that uses pulsed field ablation to treat urinary symptoms caused by an enlarged prostate (BPH). About 100 men over age 45 who haven't gotten relief from medication will receive the treatment and be followed for safety and effectiveness. The goal is to see if this approach can safely improve symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALPFA BPH Pulsed Field Ablation (PFA) System
What this could lead to: If successful, this device could offer a new, less invasive option to relieve bothersome urinary symptoms caused by an enlarged prostate.
What could go wrong: This is a small, early pilot study with no comparison group, so results may not be conclusive. The procedure also carries risks of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BENIGN PROSTATIC HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BENIGN PROSTATIC HYPERPLASIA

Contacts and locations

Locations

ASST Grande Ospedale Metropolitano Niguarda

Milan, 20162, Italy
Brno University Hospital

Brno, Czechia
Pacifica Salud Hospital

Panama City, Panama
Urologicka Klinika

Hradec Králové, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.